110 related articles for article (PubMed ID: 15565166)
1. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2.
Duechler M; Shehata M; Schwarzmeier JD; Hoelbl A; Hilgarth M; Hubmann R
Leukemia; 2005 Feb; 19(2):260-7. PubMed ID: 15565166
[TBL] [Abstract][Full Text] [Related]
2. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
3. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia.
Hubmann R; Schwarzmeier JD; Shehata M; Hilgarth M; Duechler M; Dettke M; Berger R
Blood; 2002 May; 99(10):3742-7. PubMed ID: 11986231
[TBL] [Abstract][Full Text] [Related]
4. Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL.
Hubmann R; Schnabl S; Araghi M; Schmidl C; Rendeiro AF; Hilgarth M; Demirtas D; Ali F; Staber PB; Valent P; Zielinski C; Jäger U; Shehata M
Cells; 2020 Jun; 9(6):. PubMed ID: 32570839
[TBL] [Abstract][Full Text] [Related]
5. NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells.
Hubmann R; Düchler M; Schnabl S; Hilgarth M; Demirtas D; Mitteregger D; Hölbl A; Vanura K; Le T; Look T; Schwarzmeier JD; Valent P; Jäger U; Shehata M
Br J Haematol; 2010 Mar; 148(6):868-78. PubMed ID: 19995395
[TBL] [Abstract][Full Text] [Related]
6. Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells.
Hubmann R; Hilgarth M; Schnabl S; Ponath E; Reiter M; Demirtas D; Sieghart W; Valent P; Zielinski C; Jäger U; Shehata M
Br J Haematol; 2013 Mar; 160(5):618-29. PubMed ID: 23278106
[TBL] [Abstract][Full Text] [Related]
7. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
9. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
Kelley TW; Alkan S; Srkalovic G; Hsi ED
Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
[TBL] [Abstract][Full Text] [Related]
10. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ
Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.
Morabito F; Mangiola M; Rapezzi D; Zupo S; Oliva BM; Ferraris AM; Spriano M; Rossi E; Stelitano C; Callea V; Cutrona G; Ferrarini M
Haematologica; 2003 Aug; 88(8):864-73. PubMed ID: 12935974
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
Chu S; Alexiadis M; Fuller PJ
Reprod Sci; 2009 Apr; 16(4):397-407. PubMed ID: 19087975
[TBL] [Abstract][Full Text] [Related]
13. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Yin D; Zhou H; Kumagai T; Liu G; Ong JM; Black KL; Koeffler HP
Oncogene; 2005 Jan; 24(3):344-54. PubMed ID: 15531918
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
16. Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia.
Schwarzmeier JD; Hubmann R; Düchler M; Jäger U; Shehata M
Leuk Lymphoma; 2005 Feb; 46(2):157-65. PubMed ID: 15621797
[TBL] [Abstract][Full Text] [Related]
17. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
Duechler M; Linke A; Cebula B; Shehata M; Schwarzmeier JD; Robak T; Smolewski P
Eur J Haematol; 2005 May; 74(5):407-17. PubMed ID: 15813915
[TBL] [Abstract][Full Text] [Related]
18. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
